Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 7/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | BRD2 | P25440 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413089 | 1.00 | FFAR2 (0.38) | FFAR2BRD4CREBBPBRD2AR | |
| SCHEMBL2410896 | 0.89 | BTK (0.35) | FFAR2BRD4CREBBPBRD2AR | |
| SCHEMBL2410893 | 0.89 | BTK (0.35) | FFAR2BRD4CREBBPBRD2AR | |
| SCHEMBL314817 | 0.87 | GPBAR1 (0.36) | FFAR2BRD4BRD2ARALDH1A1 | |
| SCHEMBL3398578 | 0.87 | GPBAR1 (0.36) | FFAR2BRD4BRD2ARALDH1A1 | |
| SCHEMBL315927 | 0.87 | FFAR2 (0.35) | FFAR2BRD4CREBBPBRD2KMT2A | |
| SCHEMBL3399884 | 0.87 | FFAR2 (0.35) | FFAR2BRD4CREBBPBRD2KMT2A | |
| SCHEMBL315793 | 0.83 | BRD4 (0.32) | FFAR2BRD4CYP1A2CYP3A4FFAR1 | |
| SCHEMBL315794 | 0.83 | BRD4 (0.32) | FFAR2BRD4CYP1A2CYP3A4FFAR1 | |
| SCHEMBL2409478 | 0.82 | FFAR2 (0.38) | FFAR2BRD4CREBBPBRD2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | FFAR2 4289/4885BRD4 4110/4885CREBBP 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.